Business Context and Reporting Period
Company: IsoRay, Inc. (Note: Request metadata listed "Perspective Therapeutics," but the filing text identifies the registrant as IsoRay, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2011
Business Overview: IsoRay develops and manufactures Cesium-131 brachytherapy seeds for the treatment of prostate cancer and is expanding into other modalities including lung, brain, and breast cancer. The company is a smaller reporting company listed on the NYSE Amex.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 2011 | Nine Months Ended Mar 31, 2011 |
|---|---|---|
| Product Sales (Revenue) | $1,410,694 | $3,982,743 |
| Gross Profit | $357,426 | $700,943 |
| Gross Margin | 25.4% | 17.6% |
| Operating Loss | $(693,438) | $(2,196,604) |
| Net Loss | $(1,030,265) | $(2,130,216) |
| Net Loss per Share (Basic/Diluted) | $(0.04) | $(0.09) |
| Cash and Cash Equivalents | $2,667,269 | $2,667,269 (Ending Balance) |
| Total Debt (Notes Payable) | $141,661 | $141,661 (Principal Balance) |
| Warrant Liabilities | $229,000 | $229,000 |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 17% in the three months ended March 31, 2011, compared to the same period in 2010. This was driven by an 8% increase in prostate sales and a 371% surge in "other" treatments (lung and brain modalities).
- Margin Expansion: Gross profit margin improved significantly from 4% in the prior year quarter to 25% in the current quarter. This was achieved through reduced labor costs and increased in-house pre-loading of seeds, which reduced material waste.
- Expense Reductions: Sales and marketing expenses decreased 47% quarter-over-quarter due to reductions in consulting, travel, and payroll. General and administrative expenses remained relatively stable.
- Operating Loss Improvement: The operating loss narrowed by 36% to $693,438, attributed to higher sales, lower cost of goods sold, and research and development reimbursements.
- Non-Operating Items: The company recorded a $163,000 loss on the fair value of warrant liabilities for the quarter, offsetting a $257,000 gain recorded over the nine-month period. Significant financing expenses ($174,675) were incurred due to the amortization of deferred offering costs from a November 2010 equity offering.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes cash on hand ($2.67 million) is sufficient to meet operational, debt service, and capital expenditure requirements for at least the next 12 months. Monthly cash operating expenditures were approximately $202,000.
- Future Capital Needs: To expand into new applications (head and neck, colorectal, lung) and fund protocol studies, the company anticipates needing to raise additional capital. Future financing may be dilutive to existing shareholders.
- Breakeven Target: Management estimates operational cash flow breakeven will be achieved at approximately $700,000 in monthly revenue.
- Risk Factors:
- Delisting Risk: The company narrowly met the NYSE Amex minimum stockholder equity requirement of $6 million. Failure to maintain this could result in delisting.
- Supplier Concentration: The company relies heavily on a single distributor (UralDial) for Cesium-131 from Russia and a single source for titanium tubing. Supply interruptions could materially harm production.
- Reimbursement Uncertainty: Revenue depends on third-party payer reimbursement rates (Medicare/private insurers), which are subject to annual review and potential reduction.
- Internal Controls: The company is addressing a previously identified material weakness in internal controls regarding the segregation of duties and documentation of complex transactions.
- Contingencies: The company is involved in a wrongful death claim (covered by insurance) and a dispute regarding a "know-how" royalty license, though management believes no royalties are currently due.
Investor Verification Checklist
- Listing Status: Verify current compliance with NYSE Amex listing standards, specifically the $6 million stockholder equity requirement.
- Supply Chain Security: Confirm the status of the agreement with UralDial and the availability of alternative suppliers for Cesium-131 and titanium tubing.
- Capital Raising: Monitor for announcements regarding future equity offerings, which are likely to be dilutive given the company's cash burn rate and expansion plans.
- Reimbursement Rates: Track CMS (Medicare) reimbursement code updates for brachytherapy seeds, as changes could impact demand.
- Warrant Liability: Review the fair value adjustments of warrant liabilities, as these create significant volatility in non-operating income/expense.